A Single Dose Study of Radiolabeled RO4602522 in Healthy Volunteers

NCT01631422 | Completed Phase 1

• 2 other identifiers: BP282352012-000587-26
• Study Type: interventional
• Target: 6
• Locations: 1 country
• Sites: 1

Brief Summary

This single-center, open-label study will investigate the pharmacokinetics and elimination of a radiolabelled dose of RO4602522 in healthy male volunteers. The healthy male volunteers will receive a single oral dose of RO4602522.

Conditions

Healthy Volunteer

Outcome Measures

Primary Outcomes (2)

• Pharmacokinetics: Elimination of RO4602522: urine/feces concentration

  Predose, Day 1, 2 and 3

• Pharmacokinetics: Plasma concentration of RO4602522/metabolite

  Predose, Day 1, 2 and 3

Secondary Outcomes (1)

• Pharmacokinetics: Metabolic profile of RO4602522: plasma/urine/feces concentration

  Predose, Day 1, 2 and 3

Study Arms (1)

Single Arm

EXPERIMENTAL

Drug: RO4602522

Interventions

RO4602522 DRUG

Single radiolabeled dose

Single Arm

Eligibility Criteria

• Age: 35 Years - 55 Years
• Sex: male
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy male volunteers, 35 to 55 years of age, inclusive
• Healthy status is defined by absence of evidence of any active or chronic disease following a detailed medical and surgical history, a complete physical examination including vital signs, 12-lead electrocardiogram (ECG), hematology, blood chemistry, serology and urinalysis
• A body mass index (BMI) between 18 to 30 kg/m2 inclusive
• Male volunteers and their partners of childbearing potential must use 2 methods of contraception, one of which must be a barrier method for the duration of the study and for 90 days after the last dose.
• Able to participate and willing to give written informed consent and to comply with the study restrictions.
• Non-smokers or have not smoked since at least 3 months prior to screening

You may not qualify if:

• If capable of reproduction, unwilling to use an effective form of contraception
• Suspicion of regular consumption of drug of abuse and/or positive drug or alcohol screen
• Infection with hepatitis B, hepatitis C, or human immunodeficiency virus 1 and 2
• Systolic blood pressure greater than 140 or less than 90 mm Hg, and diastolic blood pressure greater than 90 or less than 50 mm Hg
• Resting pulse rate greater than 90 or less than 45 beats per minute
• Clinically significant abnormalities in laboratory test results
• Participation in an investigational drug or device study within 90 days prior to screening
• Donation of blood within 3 months prior to screening
• Concomitant disease or condition that could interfere with, or treatment of which might interfere with, the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to the subject in this study

Sponsors & Collaborators

• Hoffmann-La Roche: lead

Study Sites (1)

Unknown Facility

Zuidlaren, 9471 GP, Netherlands

Location

MeSH Terms

Interventions

sembragiline

Study Officials

• Clinical Trials

  Hoffmann-La Roche

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 20, 2012
• First Posted: June 29, 2012
• Study Start: June 1, 2012
• Primary Completion: June 1, 2012
• Study Completion: June 1, 2012
• Last Updated: November 2, 2016

Record last verified: 2016-11

Locations

NL (1)